Characteristics of belamaf dose modifications in responders
| Belantamab mafodotin dose modifications . | DREAMM-7 Responders (n = 201) . | DREAMM-8 Responders (n = 120) . | ||
|---|---|---|---|---|
| Dose interval >3 weeks (+3-day window) . | Dose reduction . | Dose interval >4 weeks (+3-day window) . | Dose reduction . | |
| Any dose modification, n (%) | 194 (97) | 150 (75) | 119 (>99) | 83 (69) |
| Dose modifications per patient, n (%) | ||||
| 0 | 7 (3) | 47 (23) | 1 (<1) | 35 (29) |
| 1 | 25 (12) | 132 (66) | 15 (13) | 80 (67) |
| 2 | 21 (10) | 15 (7) | 16 (13) | 3 (3) |
| ≥3 | 148 (76) | 3 (1) | 88 (74) | 0 |
| Not evaluable∗ | — | 4 (2) | — | 2 (2) |
| Dose modifications, n | 1093 | 172 | 595 | 86 |
| Duration of dose delay, median (range), d | 57 (1-732) | Not applicable | 53 (1-980) | Not applicable |
| Belantamab mafodotin dose modifications . | DREAMM-7 Responders (n = 201) . | DREAMM-8 Responders (n = 120) . | ||
|---|---|---|---|---|
| Dose interval >3 weeks (+3-day window) . | Dose reduction . | Dose interval >4 weeks (+3-day window) . | Dose reduction . | |
| Any dose modification, n (%) | 194 (97) | 150 (75) | 119 (>99) | 83 (69) |
| Dose modifications per patient, n (%) | ||||
| 0 | 7 (3) | 47 (23) | 1 (<1) | 35 (29) |
| 1 | 25 (12) | 132 (66) | 15 (13) | 80 (67) |
| 2 | 21 (10) | 15 (7) | 16 (13) | 3 (3) |
| ≥3 | 148 (76) | 3 (1) | 88 (74) | 0 |
| Not evaluable∗ | — | 4 (2) | — | 2 (2) |
| Dose modifications, n | 1093 | 172 | 595 | 86 |
| Duration of dose delay, median (range), d | 57 (1-732) | Not applicable | 53 (1-980) | Not applicable |
Post hoc analysis.
Not evaluable means the patient did not receive any drug in any succeeding time period after the first dose.